← Essays Institutions

The FDA Decoded: How Regulatory Capture Works

Health regulatory agencies are structurally captured by the industries they regulate. Not through conspiracy, but through incentive design. The revolving door, user fees, information asymmetry, and career dynamics make capture inevitable.

What Capture Looks Like

Regulatory capture isn't bribery. It's structural: the regulated industry gains disproportionate influence over the regulator.

Signs:

  • Regulations burden new entrants more than incumbents
  • Approval processes favor companies with resources
  • Enforcement vigorous against small players, lenient with large
  • Standards written by industry experts who return to industry
  • Decisions consistently favor industry when ambiguous

The Mechanisms

1. The Revolving Door

FDA officials know their next job may be in pharma. Career incentives favor not making enemies. 9 of last 10 FDA commissioners went to work for pharma/biotech after leaving. You don't need to be corrupt—self-interest handles it.

2. User Fee Dependence

Since 1992 (PDUFA), FDA drug review is largely funded by fees from companies whose drugs are being reviewed. The customer is industry, not public. Review speed became a metric—fast approval pleases fee-payers. Post-market surveillance (which doesn't generate fees) got neglected.

3. Information Asymmetry

Industry knows more than regulators. Clinical trial data, manufacturing processes, market dynamics—all held by industry. Regulators depend on industry for expertise. Industry provides "education." Complex products require specialists—specialists come from industry.

4. Concentrated Benefits, Diffuse Costs

Industry has concentrated stake—billions per decision. Public interest is diffuse. Industry shows up to every meeting, funds lobbyists, hires ex-regulators. Public interest groups are understaffed. The loudest voice wins. Industry is always loudest.

Case Studies

Opioid Crisis

OxyContin approval (1995): FDA accepted Purdue's claim of low addiction risk despite thin evidence. FDA examiner Curtis Wright, who approved OxyContin, left for Purdue within two years. Structure: user fees created pressure, industry data underestimated risk, culture treated industry as partner.

Vioxx

Approved 1999. By 2000, internal Merck research showed cardiovascular risk. FDA reviewer David Graham tried to sound alarm—was pressured by supervisors. Drug stayed on market until 2004. Estimated 60,000 deaths. Structure: post-market surveillance underfunded, whistleblowers face career consequences.

GRAS (Generally Recognized As Safe)

Food additives can be deemed GRAS by manufacturers themselves—no FDA approval required. Thousands of additives entered food supply with minimal independent review. Structure: FDA lacks resources, industry self-certification = industry self-regulation.

Why It's Not Just "Bad People"

The regulator's reality:

  • Modest government salary
  • Industry offers 2-5x compensation
  • Career advancement depends on not making powerful enemies
  • Aggressive regulation = lawsuits, congressional pressure, career risk
  • Lenient regulation = smooth career, industry job waiting

Good people in bad structures produce bad outcomes. The structure is the problem.

What Individuals Can Do

  • "FDA approved" ≠ "safe" — It means approved by captured regulator. Calibrate skepticism.
  • Novel approvals warrant more skepticism — Post-market surveillance is weak. You're the guinea pig.
  • Long track records matter more — Something used safely for 50+ years is more informative than recent approval.
  • Follow independent research — Academic research (check funding), international regulators, Cochrane reviews.
  • Weight adverse events seriously — FDA's threshold for action is high.

The Principle

Regulatory Capture in Health: Health regulators are structurally captured through revolving door, user fee dependence, information asymmetry, and concentrated lobbying. "FDA approved" indicates approval by captured regulator, not safety guarantee. Weight long track records and independent research above recent regulatory approval.

How I Decoded This

Applied Corruption Stack to FDA specifically. Same capture dynamics visible in financial regulation, environmental regulation, telecom. Inference paths: incentive analysis predicts capture, historical cases confirm pattern, cross-domain consistency strengthens inference. If errors were random, directionality would be random—but errors consistently favor industry.

— Decoded by DECODER.